WO2025232801 - USE OF ANTI-FRα ANTIBODY-DRUG CONJUGATE AND PD-1 ANTAGONIST IN TREATMENT OF TUMORS
National phase entry is expected:
Publication Number
WO/2025/232801
Publication Date
13.11.2025
International Application No.
PCT/CN2025/093273
International Filing Date
08.05.2025
Title **
[English]
USE OF ANTI-FRα ANTIBODY-DRUG CONJUGATE AND PD-1 ANTAGONIST IN TREATMENT OF TUMORS
[French]
UTILISATION D'UN CONJUGUÉ ANTICORPS-MÉDICAMENT ANTI-FRα ET ANTAGONISTE DE PD-1 DANS LE TRAITEMENT DE TUMEURS
[Chinese]
抗FRα抗体药物偶联物和PD-1拮抗剂在治疗肿瘤中的应用
Applicants **
BIO-THERA SOLUTIONS, LTD.
Inventors
FU, Ziyi
ZHANG, Xinlang
ZHONG, Di
WANG, Hao
MAI, Siqi
YUE, Haitao
TANG, Weijia
SONG, Shuqiang
YU, Jin-Chen
LI, Shengfeng
Priority Data
202410574725.5
09.05.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2783 | |
| EPO | Filing, Examination, Granting | 28468 | |
| Japan | Filing, Examination, Granting | 3143 | |
| South Korea | Filing, Examination, Granting | 4264 | |
| USA | Filing, Examination, Granting | 10140 |
Total:
48,798
Contact Us
Abstract[English]
The present invention relates to a use of an anti-FRα antibody-drug conjugate and a PD-1 antagonist in treatment of tumors. A treatment method comprises administering to a patient in need thereof an effective amount of an anti-FRα antibody-drug conjugate and an effective amount of a PD-1 antagonist.[French]
La présente invention concerne l'utilisation d'un conjugué anticorps-médicament anti-FRα et d'un antagoniste de PD-1 dans le traitement de tumeurs. Une méthode de traitement comprend l'administration à un patient qui en a besoin d'une quantité efficace d'un conjugué anticorps-médicament anti-FRα et d'une quantité efficace d'un antagoniste de PD-1.[Chinese]
本发明涉及抗FRα抗体药物偶联物和PD-1拮抗剂在治疗肿瘤中的应用，治疗方法包括向有需要的患者给药有效量的抗FRα抗体药物偶联物和PD-1拮抗剂。